NASDAQ:SRRK

Scholar Rock Holding Stock News

etoro logo Buy SRRK
*Your capital is at risk
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Scholar Rock Q1 Earnings Call Highlights

10:06pm, Friday, 08'th May 2026
Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company's investigational treatment for
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi
Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) COO Keith Woods sold 10,220 shares of the business's stock in a transaction on Thursday, April 16th. The stock was sold at an average
Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an av
Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) CFO Vikas Sinha sold 10,410 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi
Scholar Rock (SRRK) is transitioning from regulatory uncertainty to a clear execution path for a 2026 US launch of apitegromab. Resolution of FDA manufacturing concerns at Catalant's facility and resu
E. Ohman J or Asset Management AB cut its position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 76.6% in the undefined quarter, according to the company in its most recent Form 13F
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE